Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Nov
15
Today In Oncology
Pancreatic Cancer Mild Duct Dilation May Serve as Early Indicator in High-Risk Patients
Preliminary Activity of LuPSMA-IT Plus Ra-223 in Metastatic Castration-Resistant Prostate Cancer With Bone Metastasis
Pembrolizumab Plus Weekly Paclitaxel Improves Survival Outcomes in Platinum-Resistant Recurrent Ovarian Cancer
SABR May Be Comparable to Surgery for Early-Stage NSCLC
MD Anderson Launches 2.5 Billion Philanthropic Campaign
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo